The $16.4 Billion Crisis Hiding in Plain Sight Across Canada's Economy

OTTAWA, ON – June 16, 2026 – A staggering new report has pulled back the curtain on one of the most significant, yet often misunderstood, pressures on Canada’s healthcare system and broader economy. Substance use—spanning everything from a nightly glass of wine to the escalating opioid crisis—cost the nation’s healthcare system $16.4 billion in 2024 alone, with one in every ten people admitted to a hospital there due to its impact.

The landmark report, released today by the Canadian Centre on Substance Use and Addiction (CCSA) and the University of Victoria's Canadian Institute for Substance Use Research (CISUR), dismantles the common misconception that these costs are primarily driven by illicit drug addiction. Instead, it paints a far more pervasive picture, revealing a systemic issue deeply embedded in the everyday lives of Canadians and the very structure of our healthcare delivery.

The Hidden Burden of Legal Vices

While the opioid crisis rightfully captures headlines, the report’s most sobering financial revelation is the colossal economic footprint of legal substances. Alcohol and tobacco, two of the most socially integrated psychoactive substances, are the primary drivers of the $16.4 billion bill, accounting for a combined 90% of the total cost. Alcohol use alone contributed to $7.8 billion in healthcare expenses, while tobacco followed closely at $6.8 billion.

This data forces a critical shift in perspective. The issue is not confined to a small fraction of the population struggling with addiction. Rather, it’s a mainstream phenomenon with profound economic consequences. The report, titled 'Canadian Substance Use Costs and Harms (CSUCH) – Healthcare 2017-2024,' notes that the vast majority of the nearly 300,000 substance-related hospitalizations in 2024 were not for substance use disorders themselves. They were for the downstream health effects: the cancers, cardiovascular diseases, liver conditions, and injuries that are the long-term, and often silent, consequences of regular use.

"To put this into perspective, you do not need to have a substance use disorder for your health to be impacted by substance use," explained lead researcher Dr. Anat Ziv, a Research and Policy Analyst at CCSA. This point is underscored by the finding that approximately 87% of Canadian adults reported using at least one psychoactive substance in the past year. The report effectively argues that what many consider moderate, socially acceptable behavior is contributing to a system-wide strain that is both medically and economically unsustainable. The costs are not just borne by individuals but are socialized across the entire healthcare infrastructure, impacting wait times, resource availability, and the system’s capacity to handle other health crises.

A System-Wide Strain, Not a Niche Problem

The report makes it unequivocally clear that substance use is not a niche issue siloed within addiction clinics or emergency rooms. With 12% of all hospitalizations in Canada linked to substance use, its effects permeate every ward and specialty. From oncology to cardiology to orthopedics, healthcare professionals are treating the consequences, whether they are explicitly aware of the root cause or not. This represents a massive, and largely untracked, operational burden on hospitals and clinics nationwide.

The $16.4 billion figure is broken down into tangible economic pressures: $4.9 billion for prescription medications, $4.6 billion for in-patient hospitalizations, and $3.9 billion for physician time. Each of these figures represents a diversion of finite resources—beds, specialists, and funding—that could be allocated elsewhere. As one public health economist noted, "This isn't just a health cost; it's an opportunity cost for the entire system."

Dr. Adam Sherk, a senior scientist involved in the study, emphasized this broader context. "Substance use is more than just a personal issue. It has wide social, economic and healthcare system impacts that are felt throughout communities across Canada," he stated. The report serves as a powerful analytical tool, allowing for a more strategic allocation of resources. The data suggests a need to integrate substance use awareness and intervention into routine primary care, rather than waiting for a crisis to manifest. Shockingly, the $16.4 billion figure only accounts for direct healthcare costs. The CSUCH project will release further reports later this year detailing costs related to lost productivity and the criminal justice system, promising an even larger and more daunting economic picture.

Opioids and the Economics of a Toxic Market

While alcohol and tobacco form the massive base of the cost pyramid, the most alarming trend is the rapid escalation of costs associated with opioids. Though accounting for a smaller portion of the total (4.4%), per-person healthcare costs for opioid use surged by approximately 30% between 2017 and 2024. The report directly links this spike to the lethal dynamics of a "toxic and unstable unregulated drug market."

This is where public health intersects with failed market regulation. The proliferation of illicitly manufactured fentanyl and other synthetic opioids has turned a public health challenge into an acute, high-mortality crisis. Each overdose, whether fatal or not, triggers a cascade of high-cost emergency services, intensive care, and long-term medical support. This 30% increase is the financial echo of the human tragedy documented in coroners' reports across the country. The unregulated market operates without quality control, leading to unpredictable potency and a constant risk of death for users, which in turn drives up emergency response costs at an exponential rate. Experts suggest that these figures make a powerful economic case for expanding harm reduction services, such as safer supply programs, which could mitigate these exorbitant emergency costs by providing a regulated alternative to the toxic street supply.

A Call for Data-Driven Policy Innovation

Ultimately, the CSUCH report is more than a summary of costs; it is a strategic blueprint for innovation in public health policy. By quantifying the specific impacts of different substances, it provides policymakers with the evidence needed to move beyond a one-size-fits-all approach. The data challenges governments to look beyond the opioid crisis and confront the deeply entrenched, and far more costly, harms of alcohol and tobacco with renewed vigor.

Internationally, Canada's situation is not unique, as nations from the U.S. to Australia grapple with similar challenges. However, the report’s detailed, substance-by-substance breakdown provides a unique advantage for targeted intervention. It highlights the need for policies that address the availability, pricing, and marketing of legal substances while simultaneously implementing urgent, evidence-based strategies to combat the unregulated drug market. Dr. Sherk noted that the data allows officials to "prioritize more effective responses." This data-driven approach is essential for navigating a complex landscape where public perception often lags behind economic and medical reality, creating a pathway to a healthier population and a more resilient economy.